Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 80425-0134

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 80425-0134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Pharmacy Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2

A line graph titled 'Mean Daytime Heartburn Scores RAB-USA-2' showing mean heartburn scores over study days for three groups: placebo (n=68), Rabeprazole 10 mg (n=64), and Rabeprazole 20 mg (n=67). The y-axis represents heartburn mean scores from 0 (None) to 4 (Very Severe), and the x-axis represents study days from -14 to 28. Scores for Rabeprazole groups decrease after day 0, indicating reduction in heartburn severity compared to placebo.*

FDA Label Image

Figure 4

A line graph titled 'Mean Daytime Heartburn Scores RAB-USA-3' displaying heartburn scores over study days, from -14 to 28. The y-axis shows mean heartburn scores from 0 (None) to 4 (Very Severe). Two groups are compared: Placebo (dashed line) and RAB 20 mg (solid line). Scores decrease notably for RAB 20 mg after day 0, indicating lower heartburn severity compared to placebo over the study period.*

FDA Label Image

Figure 5

This is a line graph titled 'Mean Nighttime Heartburn Scores RAB-USA-3' showing mean scores on the y-axis (range 0 to 4) against study days on the x-axis (-14 to 28). Two groups are depicted: placebo (n=58) with a dashed line and Rabeprazole Sodium 20 mg (n=59) with a solid line. Scores decrease after study day 0 for both groups, with Rabeprazole Sodium maintaining slightly lower scores during the study period. Heartburn severity ranges from 0 (None) to 4 (Very Severe).*

FDA Label Image

Rabeprazole Sodium Dr Qty 30 Ndc 80425 0134

The label for Rabeprazole Sodium DR 20 mg delayed release tablets from Advanced Rx Pharmacy of Tennessee, LLC shows the proprietary and generic names, strength, and dosage form. It includes the quantity (#30), NDC number (80425-0134-01), a comparison to ACIPHEX, lot number, expiration date (08/31/2022), storage instructions, and barcodes. The label also contains a caution about federal law regarding drug transfer.*

FDA Label Image

Rabeprazole Sodium Dr Qty 60 Ndc 80425 0134

Packaging label for Rabeprazole Sodium DR 20 mg delayed release tablets by Advanced Rx Pharmacy of Tennessee, LLC. The label includes comparison to Aciphex, an NDC reference, lot number 60RAB20822, and an expiration date of 8/31/2022. Storage instructions specify room temperature (20°-25°C or 68°-77°F). The label features a barcode and contact information for the labeler in Nashville, TN.*

FDA Label Image

Structure

Chemical structure of Rabeprazole Sodium, the active ingredient, showing its molecular arrangement including a sodium atom, nitrogen-containing rings, a sulfur-oxygen group, and a methoxy-ethoxy side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.